Watson-Kissei’s Silodosin For BPH Could Have Oct. 14 User Fee Date
This article was originally published in PharmAsia News
Executive Summary
Generic specialist Watson Pharmaceuticals and Japan's Kissei Pharmaceutical said Feb. 13 that the U.S. FDA had accepted their filing of a new drug application for silodosin to treat signs and symptoms associated with benign prostatic hyperplasia